Cas9 Sandbox: Difference between revisions
No edit summary |
No edit summary |
||
| Line 22: | Line 22: | ||
[[Image:Layout for schematic and structure with structure.png|660px]] | [[Image:Layout for schematic and structure with structure.png|660px]] | ||
[[Image:4un3 labeled.png|right|390px]] | [[Image:4un3 labeled.png|right|390px]] | ||
==Limitations== | |||
Despite the many advantages of CRISPR/Cas9 it still has two major limitations. The first is that CRISPR/Cas9 requires the presence of an NGG PAM. NGG PAM occurs approximately every 8bp causing it CRISPR/Cas9 to have less target sequence density than TALENS. This lower precision compared to TALENS may lead to CRISPR/Cas9 being used less in cases where a DSB needs to be targeted in smaller sequences. The next limitation is the use of DSBs. If cleavage occurs at an off-target site the genome can experience unexpected perturbations. As CRISPR/Cas9 and other genome editing methods move to a more clinical use these perturbations could increase the risk of developing tumors.<ref>PMID: 27218233</ref> | |||
==Medicinal Applications== | ==Medicinal Applications== | ||